Related Experiment Video
Updated: Aug 9, 2026

Modified Technique for Coronary Artery Ligation in Mice
Published on: March 29, 2013
Timolol treatment after myocardial infarction in diabetic patients
Insights
Long-term timolol treatment significantly reduced mortality and reinfarction in diabetic patients post-myocardial infarction. Diabetic patients responded similarly to non-diabetic patients, though slight carbohydrate intolerance was noted.
Area of Science:
- Cardiology
- Diabetology
- Pharmacology
Background:
- Diabetic patients face increased risks following myocardial infarction.
- Beta-blocker therapy is standard post-myocardial infarction, but data in diabetics is limited.
Purpose of the Study:
- To evaluate the efficacy of long-term timolol treatment in diabetic patients after myocardial infarction.
- To compare outcomes between diabetic patients receiving timolol and placebo.
Main Methods:
- Retrospective analysis of 99 diabetic patients from the Norwegian timolol multicenter study.
- Timolol dosage: 10 mg twice daily; follow-up: 12-33 months (mean 17 months).
Main Results:
- Timolol reduced overall mortality by 62.8% (P<0.05) and nonfatal reinfarction by 82.7% (P<0.05) compared to placebo.
- Diabetic patients showed similar responses in side effects and withdrawals as non-diabetic patients.
- A potential for slight carbohydrate intolerance with long-term timolol use was observed.
Conclusions:
- Long-term timolol treatment is associated with significant reductions in mortality and reinfarction in diabetic patients post-myocardial infarction.
- Diabetic patients tolerated timolol similarly to non-diabetic patients.
- Prospective studies are needed to confirm these findings and monitor for carbohydrate intolerance.
Abstract:
In diabetic patients long-term treatment with timolol after myocardial infarction was related to a reduction in overall mortality, total cardiac death, sudden death, and nonfatal reinfarction, compared with patients in a placebo group. The analyses were based on 99 diabetic patients in the Norwegian timolol multicenter study. The dosage of timolol was 10 mg twice daily and the follow-up period was 12-33 mo (mean: 17 mo). When analyzing all randomized patients, there were 14 deaths in the placebo group and 6 deaths in the timolol group, a reduction of 62.8% (P less than 0.05). The number of nonfatal reinfarctions was 10 in the placebo group and 2 in the timolol group, a reduction of 82.7% (P less than 0.05). With regard to inclusion rate, side effects, withdrawals, and timolol-related reduction in mortality and reinfarction, the diabetic patients basically behaved like nondiabetic patients. The data were analyzed retrospectively and should be confirmed by a prospective study. The study also indicates that long-term treatment with timolol may induce slight carbohydrate intolerance.
More Related Videos
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Mitral Regurgitation III: Medical Management
Myocarditis III: Medical Management
Diabetic Retinopathy